GSK's CEO Witty wants U.K. focus on manufacturing

GlaxoSmithKline ($GSK) CEO Andrew Witty (photo) said the U.K. needs to positively rebalance its economy, while growing the private sector with a focus on manufacturing, according to Social Enterprise. But trust in the private sector has eroded, he said, and business leaders have to lead by example in terms of corporate responsibility. Article

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.